Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-05-27 4:34 pm Sale | 13D | GENOCEA BIOSCIENCES INC GNCA | New Enterprise Associates 16 L.P. | 0 0% | -15,414,495 (Position Closed) | View |
| 2022-02-14 4:09 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | COMMODORE CAPITAL LP | 3,079,756 5.4% | 208,132 (+7.25%) | View |
| 2022-02-14 06:19 am Sale | 13G | GENOCEA BIOSCIENCES INC NE GNCA | CITADEL ADVISORS LLC | 3,535,358 6.2% | -51,718 (-1.44%) | View |
| 2022-02-11 7:54 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | BIOTECHNOLOGY VALUE FUND L P | 5,930,353 9.99% | 644,804 (+12.20%) | View |
| 2022-02-10 4:55 pm Purchase | 13G | GENOCEA BIOSCIENCES INC GNCA | GSK plc GSK | 5,861,389 9.9% | 644,000 (+12.34%) | View |
| 2021-04-13 7:08 pm Sale | 13D | GENOCEA BIOSCIENCES INC GNCA | New Enterprise Associates 16 L.P. | 15,414,495 26.3% | -1,558,333 (-9.18%) | View |
| 2021-03-31 07:14 am Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | COMMODORE CAPITAL LP | 2,871,624 5.4% | 2,871,624 (New Position) | View |
| 2021-02-16 4:30 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | CITADEL ADVISORS LLC | 3,587,076 6.7% | 154,690 (+4.51%) | View |
| 2021-02-16 09:57 am Sale | 13G | GENOCEA BIOSCIENCES INC NE GNCA | UBS OCONNOR LLC | 1,769,170 3.3% | -290 (-0.02%) | View |
| 2021-02-12 5:12 pm Purchase | 13G | GENOCEA BIOSCIENCES INC GNCA | GSK plc GSK | 5,217,389 9.9% | 1,540,622 (+41.90%) | View |
| 2021-02-12 5:03 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | BIOTECHNOLOGY VALUE FUND L P | 5,285,549 9.99% | 2,123,881 (+67.18%) | View |
| 2021-02-12 4:30 pm Sale | 13G | GENOCEA BIOSCIENCES INC GNCA | Vivo Opportunity LLC | 613,437 1.2% | -830,401 (-57.51%) | View |
| 2021-02-12 08:04 am Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | Avoro Capital Advisors LLC | 33,613,444 9.99% | 33,613,444 (New Position) | View |
| 2020-08-03 2:22 pm Purchase | 13D | GENOCEA BIOSCIENCES INC GNCA | New Enterprise Associates 16 L.P. | 16,972,828 48.7% | 8,004,211 (+89.25%) | View |
| 2020-07-31 4:31 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | CITADEL ADVISORS LLC | 3,432,386 6.5% | 3,432,386 (New Position) | View |
| 2020-02-28 4:48 pm Unchanged | 13G | GENOCEA BIOSCIENCES INC GNCA | GSK plc GSK | 3,676,767 13.3% | 0 (Unchanged) | View |
| 2020-02-14 5:00 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | BIOTECHNOLOGY VALUE FUND L P | 3,161,668 6.5% | 3,161,668 (New Position) | View |
| 2020-02-14 4:39 pm Sale | 13G | GENOCEA BIOSCIENCES INC GNCA | GSK plc GSK | 3,676,767 7.7% | -10,880,237 (-74.74%) | View |
| 2020-02-13 5:53 pm Sale | 13G | GENOCEA BIOSCIENCES INC GNCA | Vivo Opportunity LLC | 1,443,838 3% | -6,736,162 (-82.35%) | View |
| 2020-02-13 4:49 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | UBS OCONNOR LLC | 1,769,460 6.3% | 1,769,460 (New Position) | View |